Member Directory

Below all members are listed in alphabetical order. Click the tabs above to view working group members.

Dr. Abrams is a Professor of Epidemiology and Pediatrics at Columbia University with over 35 years of experience in the prevention and treatment of HIV infection and associated infectious diseases in pregnant women, children, and their families. As the Senior Director for Research at ICAP, she leads ICAP’s large research agenda and is responsible for the development of technical assistance and service programs for pediatric and perinatal prevention initiatives for ICAP programs in sub-Saharan Africa and Asia.

Nicole Ammerman is a Research Associate in the Department of Medicine, Division of Infectious Diseases, at the Johns Hopkins University School of Medicine. She has a PhD in Microbiology and Immunology from the University of Maryland School of Medicine and an ScM in Epidemiology from the Johns Hopkins University Bloomberg School of Public Health. Her research focuses on the experimental chemotherapy of tuberculosis and nontuberculous mycobacterial diseases.

Terrence F. Blaschke, MD, is Professor of Medicine and Molecular Pharmacology (Emeritus) at Stanford University, Adjunct Professor of Bioengineering and Therapeutic Sciences at UCSF and Adjunct Professor of Medicine at Indiana University. He joined the faculty at Stanford University School of Medicine in 1974. Dr. Blaschke was a member of the AIDS Clinical Trials Group and served as chair of the Pharmacology Committee.

Dr. Bollinger is Founding Director of the Center for Clinical Global Health Education (CCGHE) and Professor of Infectious Diseases at the Johns Hopkins University (JHU) School of Medicine. He holds joint appointments in international health at the Johns Hopkins (JH) Bloomberg School of Public Health, and in community public health at the JH School of Nursing.

Richard E. Chaisson, MD, is Professor of Medicine, Epidemiology, and International Health at Johns Hopkins University and Director of the Johns Hopkins Center for TB Research and the Center for AIDS Research.

.

Daniel E Cohen, MD, is a Group Medical Director in Clinical Development at AbbVie, where his areas of responsibility include viral diseases and cystic fibrosis. Dr. Cohen has extensive experience in clinical drug development for HIV and hepatitis C, and has been involved in the approval of Viekira Pak, Technivie, and Mavyret. 

Tine has a PhD in Veterinary Sciences from the University of Ghent, Belgium and earned her MBA in Pharmaceutical Management from Drexel LeBow College of Business. She has additional Masters degrees in Biology and Teaching. Tine is Compound Development Team Lead for Tuberculosis at Johnson & Johnson Global Public Health.

Paul is accountable for developing and transferring for manufacture better and less expensive chemistries, formulations, and fixed-dose combination products for adults and children; supporting treatment optimization through the development, regulatory filing, and quality assessment of new products, diagnostics, and devices; providing clinical guidance on managing diseases and transitioning to new treatment paradigms;

Dr. Feld attended medical school at the University of Toronto and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr. Feld focused on developing skills in clinical and laboratory research in liver disease, with a particular interest in viral hepatitis. 

Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP). He is Professor of Medicine in the Divisions of Clinical Pharmacology and Infectious Diseases, and Professor of Pharmacology and Molecular Sciences in the Johns Hopkins University School of Medicine. He is also Professor of International Health in the Johns Hopkins University Bloomberg School of Public Health.

Daria Hazuda, PhD, trained as a biochemist at the State University of New York at Stony Brook, N.Y. After completing her postdoctoral research fellowship in the department of Immunology at Smith Kline, she joined the antiviral research group as a Senior Research Biochemist at Merck in 1989.

Magali Hickey is the Director of Formulation Development at Alkermes Inc., a global biotechnology organization with a research and development facility located in Waltham, MA. Magali has over 10 years of experience in the pharmaceutical industry with interests focused on development of small molecules into viable drug products.

Dr. Rodney JY Ho is a distinguished professor of pharmaceutics (SOP), adjunct professor of bioengineering (SOM) and is an inaugural presidential entrepreneurial fellow of the University of Washington. He is also a member of Fred Hutchinson Cancer Research Center. His research encompasses basic and translational sciences for improving the therapeutic efficacy and safety of viral and cancer drugs, diagnostic agents and vaccines.

Jeffrey M. Jacobson, MD is Professor of Medicine and Neuroscience and Co-Director, Center of Translational AIDS Research Lewis Katz School of Medicine at Temple University. He has extensive experience in the care and investigative study of HIV-infected patients. His particular focus of research has been on the immunology and immunopathogenesis of HIV-1 infection, including vaccine, gene and other immune-based therapies, as well as monoclonal antibody development.

Leah Johnson, PhD, is a Senior Research Chemist in the Center for Engineered Systems at RTI International. Dr. Johnson’s research interests include the design and development of polymer-based biosensors and drug delivery systems and translation to early stage products. She currently leads a research group focused on the development long-acting biodegradable implants for prevention and treatment of HIV and as a multipurpose prevention technology

In 1996, Andy began volunteering at Christie’s Place, an agency serving women, children, and families impacted by HIV/AIDS in San Diego.  This led to an interest in HIV and other types of medical research. His past and current work has included treatment and research education, support group facilitation, and patient advocacy.

Daniel R. Kuritzkes, MD received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University, and his MD from Harvard Medical School. He completed his clinical and research training in internal medicine and infectious diseases at Massachusetts General Hospital and was a visiting scientist at the Whitehead Institute for Biomedical Research before joining the faculty at the University of Colorado Health Sciences Center. 

Mila Maistat works as Policy and Advocacy Manager with the Medicines Patent Pool (MPP). She has almost 20 years of experience of working in public health, in particular, viral hepatitis and HIV policy, advocacy and access to medicines. Mila has been serving with WHO as a member of WHO STAC on viral hepatitis and the WHO guidelines’ development and peer-review groups, development of regional and country plans on HIV, viral hepatitis and TB, used to chair HepC Group for the UNITAID NGO delegation, member of HIV, viral hepatitis and TB in Europe Steering Committee, part of organizing and scientific committees for international conferences and meetings on viral hepatitis and HIV.

Craig McClure leads the Viral Hepatitis Program at the Clinton Health Access Initiative (CHAI). In this capacity, he directs a global team supporting seven countries in Africa and Asia to scale up diagnosis and treatment of viral hepatitis, with an emphasis on hepatitis C, including market-shaping interventions to introduce innovations in diagnostics and drugs, increase volumes and drive down pricing, support for policy and program development, financing, training of health workers, and monitoring and evaluation.

Ms. McKenzie-White is Managing Director and Senior Program Officer at the Center for Clinical Global Health Education. She has more than 20 years of experience in program leadership, web development, health education, and research. Since joining CCGHE in 2006, her efforts have focused on distance learning and capacity-building. Her work has contributed to numerous peer-reviewed publications on leveraging technology to facilitate clinical global health education and optimize healthcare delivery.

Mark Mirochnick, M.D. is Professor of Pediatrics and a member of the Division of Neonatology at Boston University School of Medicine/Boston Medical Center. He has extensive experience in clinical trials investigating the clinical pharmacology of antiretrovirals and TB drugs in neonates, infants, children and pregnant women.

Dr. Nuermberger is an Associate Professor of Medicine and International Health at Johns Hopkins University. His primary research interest is the experimental chemotherapy of TB. The work uses well-validated murine models of active TB and latent TB infection to evaluate the efficacy of promising new antimicrobials.

David has >20 years of infectious disease drug discovery experience with a focus on HIV-1 and HCV. In 2011 he was given the responsibility of directing Merck’s Neglected Tropical Disease discovery efforts that includes tuberculosis, macrofilaria, Chagas, Leishmania, malaria and Ebola.

Andrew Owen is a Professor in the Department of Molecular and Clinical Pharmacology at the University of Liverpool. He is also affiliated to the MRC Centre for Drug Safety Science and the Wolfson Centre for Personalised Medicine. He is Chair of the British Society for Nanomedicine, a fellow of the Royal Society of Biology, and a member of the steering committee for the Academy of Pharmaceutical Sciences Nanomedicines Focus Group. 

Dr. Chuck Peloquin received his BS in Pharmacy from the University of Connecticut and his Doctor of Pharmacy from the Philadelphia College of Pharmacy and Science. 

Dr. Podany is currently an Assistant Professor in the department of pharmacy practice at the University of Nebraska Medical Center.

Dr. Rangaka is an Associate Professor within the Institute of Global Health, University College London (UCL), United Kingdom. She is also affiliated to the MRC Clinical Trials Unit at UCL and is an honorary Associate Professor at the University of Cape Town (UCT), South Africa.

Bart Remmerie, Chem. Eng., graduated as a bio-engineer and as environmental engineer at Ghent University, Belgium. He started at Janssen (Bioanalysis) in 1994 and joined the Clinical Pharmacology group in 2006, initially primarily working on neuroscience projects, and more recently also on anti-infectives. 

Dr. James F. Rooney joined Gilead Sciences in 1996 as Vice President of Clinical Research and in 2004 became Vice President of Medical Affairs. From 2004 to 2006, he was also Vice President of Drug Safety and Public Health. Dr. Rooney has been instrumental in the clinical development of the company's antiviral therapies, including treatments for HIV, hepatitis B and influenza.

Kimberly Scarsi is an Associate Professor at the University of Nebraska Medical Center’s (UNMC) College of Pharmacy. Her research program focuses on optimizing pharmacologic therapies for persons living with HIV, with an emphasis on global health and sex/gender related issues.

Dr Marco Siccardi graduated with an MSc in Clinical Biology (2006) at the University of Turin, Italy. He obtained his PhD at the University of Liverpool, Liverpool, UK (2011) focusing his research on molecular mechanisms influencing drug distribution and predictors of exposure in patients. He was recently appointed as a Lecturer in Pharmacology across the faculties of Health & Life Sciences and Science & Engineering at the University of Liverpool. 

Dr. Patrick J. Sinko is a distinguished professor (II) of Pharmaceutics at Rutgers, The State University of New Jersey in the Ernest Mario School of Pharmacy and is also Associate Vice President in the Office of Research and Economic Development. His lab focuses on biopharmaceutics, pharmaceutical formulations, and nanoscale drug delivery with specific applications to AIDS, breast and lung cancer, chemical terrorism countermeasures and TB.

Bill Spreen, Pharm.D, is a Director of Research and Development at ViiV Healthcare and based in Research Triangle Park, North Carolina. Currently, he is Medicine Development Leader for the HIV integrase inhibitor cabotegravir, a long-acting injectable agent under investigation for both HIV prevention and treatment.

Kimberly Struble, PharmD, is a Senior Clinical Team Leader in the Division of Antiviral Products at the Food and Drug Administration. She provides expertise in all phases of antiviral clinical drug development and leads a team responsible for the development of new products for the treatment and prevention of HIV infection, hepatitis B and C, influenza, various herpes infections, and other emerging viral infections. 

Mark Sulkowski, MD, is a Professor of Medicine at the Johns Hopkins University School of Medicine and the Director of the Division of Infectious Diseases Johns Hopkins Bayview Medical Center. He also serves as the Medical Director of the Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology in the Department of Medicine and is the Associate Dean for Research in the Capital Region (CAPRES). 

Susan Swindells is a Professor of Internal Medicine in the Section of Infectious Diseases at the University of Nebraska Medical Center, USA.  A native of England, Dr. Swindells earned her medical degree from University College London in 1977, with postgraduate training in England and at the University of Washington in Seattle.  She has been involved in HIV care since 1984. 

David Thomas is Director of Infectious Diseases and the Stanhope Bayne-Jones Professor of Medicine at the Johns Hopkins School of Medicine. His research is focused on hepatitis viruses, especially interactions between HIV and viral hepatitis. Dr. Thomas has served the National Institutes of Health and leading professional societies and the associated biomedical journals in multiple leadership/editorial capacities.

Peter leads teams investigating novel interventions against HIV-1, within the R&D group of Janssen’s Global Public Health organization. He is project leader for rilpivirine long acting, the injectable nanosuspension formulation being investigated for treatment and prophylaxis against HIV.